Citi Maintains Hold on Amylin Pharmaceuticals

Citi is out with its report today on Amylin Pharmaceuticals AMLN, maintaining Hold. In its report, Citi writes, "We rate the shares of Amylin Hold/Speculative. In our view, ongoing concerns about Bydureon's safety profile relating to QTc prolongation are the key overhang on the stock. In our view, Bydureon is overall safe and likely does not have a major QTc issue. We expect approval by FDA in early-'12." Citi maintains a $15 PT on AMLN. At the time of posting, shares of AMLN were trading at $10.41, down 2.07% from Friday's close.